Her-2和胃癌诊疗进展  

Progress in diagnosis and treatment of Her- 2 in gastric cancer

作　　者：寇梦瑛 王朝阳[2] 

机构地区：[1]广东医学院,广东湛江524000 [2]汕头大学医学院附属粤北人民医院放疗科,广东韶关512026

出　　处：《现代肿瘤医学》2015年第8期1139-1141,共3页Journal of Modern Oncology

摘　　要：胃癌的治疗效果不佳,提倡个体化治疗,生物标记物是筛选个体化治疗的重要手段。人类表皮生长因子受体2(human epidermal growth factor receptor 2,Her-2)在胃癌组织中高表达,与胃癌的预后相关,可指导晚期胃癌的分子靶向治疗。Her-2状态还可能和晚期胃癌患者化疗敏感性相关,并可指导胃癌术后辅助治疗获益人群的筛选。The treatment effect of gastric cancer is poor currently. We promote the individualized treatment. Biomark- ers are important means of screening individualized treatment. Human epidermal growth factor receptor 2 （ Her - 2） is increased in gastric cancer tissue. It is associated with the prognosis of gastric cancer, can guide the molecular target therapy for advanced gastric cancer. Moreover, Her - 2 status may be related to chemotherapeutic sensitivity and screen the gastric cancer patients who can be benefited from postoperative adjuvant therapy.

关 键 词：人类表皮生长因子受体2 胃癌 预后 靶向治疗 辅助治疗 

分 类 号：R735.2[医药卫生—肿瘤]